The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer
Elevated GDF-15 expression in NSCLC tumor tissues is associated with poorer response to nivolumab, suggesting that GDF-15 is a potential prognostic biomarker for immunotherapy efficacy. These findings warrant further validation through prospective studies to optimize treatment strategies for NSCLC patients.
Authors
- Nuriye Özdemir (ORCID: https://orcid.org/0000-0002-9235-9592)
- Orhun Akdoğan (ORCID: https://orcid.org/0000-0003-0212-1191)
- Nalân Akyürek (ORCID: https://orcid.org/0000-0002-2644-4609)
- Ahmet Özet (ORCID: https://orcid.org/0000-0001-8731-9636)
- Osman Sütçüoğlu (ORCID: https://orcid.org/0000-0003-3835-2741)
- Fatih Gürler (ORCID: https://orcid.org/0000-0003-0023-5793)
- Betül Öğüt (ORCID: https://orcid.org/0000-0002-1385-7324)
- Ozan Yazıcı (ORCID: https://orcid.org/0000-0003-0038-3569)
- Ayşenur Sert
Institutions
- Gazi University (TR)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1186/s12885-024-12727-3
- Citations
- 9
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.23